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The mitogen-activated protein kinase (MAPK) p38/MAPK-activated protein kinase 2 (MK2) signaling
pathway plays an important role in the posttranscriptional regulation of tumor necrosis factor (TNF), which
is dependent on the adenine/uridine-rich element (ARE) in the 3 untranslated region of TNF mRNA. After
lipopolysaccharide (LPS) stimulation, MK2-deficient macrophages show a 90% reduction in TNF production
compared to the wild type. Tristetraprolin (TTP), a protein induced by LPS, binds ARE and destabilizes TNF
mRNA. Accordingly, macrophages lacking TTP produce large amounts of TNF. Here, we generated MK2/TTP
double knockout mice and show that, after LPS stimulation, bone marrow-derived macrophages produce TNF
mRNA and protein levels comparable to those of TTP knockout cells, indicating that in the regulation of TNF
biosynthesis TTP is genetically downstream of MK2. In addition, we show that MK2 is essential for the
stabilization of TTP mRNA, and phosphorylation by MK2 leads to increased TTP protein stability but reduced
ARE affinity. These data suggest that MK2 inhibits the mRNA destabilizing activity of TTP and, in parallel,
codegradation of TTP together, with the target mRNA resulting in increased cellular levels of TTP.
The p38 mitogen-activated protein kinase (MAPK) pathway
is activated by stress and inflammatory stimuli. One of the
major and best understood functions of this module is post-
transcriptional regulation of mRNAs containing adenylate/urid-
ylate-rich elements (AREs) in their 3 untranslated region
(3UTR) (13, 14, 30, 31). AREs that contain the pentamer
AUUUA are wide spread, and a computational estimation
suggests that as much as 8% of human genes contain functional
AREs, making a total of 2,800 to 9,600 ARE-containing tran-
scripts (1, 2). Experimentally, the p38 pathway has been im-
plicated in the regulation of mRNA stability of cyclooxygenase
2, tumor necrosis factor alpha (TNF-), interleukin-3 (IL-3),
IL-6, IL-8, macrophage inhibitory protein 1, granulocyte-
macrophage colony-stimulating factor (GM-CSF), vascular en-
dothelial growth factor, urokinase-type plasminogen activator,
and inducible NO synthase (13–15, 30, 31).
MAPK-activated protein kinase 2 (MK2) is one of several
downstream targets of p38. The generation and analysis of
MK2-deficient mice demonstrated that MK2 is the major ki-
nase downstream of p38 responsible for posttranscriptional
regulation of cytokine biosynthesis. Spleen cells of MK2-defi-
cient mice produced levels of TNF, IL-6, and gamma inter-
feron that were 10 to 20% of those of wild type (WT) cells after
lipopolysaccharide (LPS) stimulation (20). The effect of MK2
on TNF biosynthesis is directly dependent on the ARE in the
3UTR of TNF mRNA (28).
The zinc finger protein tristetraprolin (TTP), also known as
Nup 475, TIS11, G0S24, or ZFP36, mediates TNF mRNA
instability in macrophages by directly binding to its ARE. TTP-
deficient mice have a systemic inflammatory syndrome with
severe polyarticular arthritis and autoimmunity, as well as
medullary and extramedullary myeloid hyperplasia (11). The
syndrome is predominantly due to excess circulating TNF, re-
sulting from the increased stability of the TNF mRNA and
subsequent higher rates of secretion of the cytokine. The my-
eloid hyperplasia might be due in part to increased stability of
granulocyte-macrophage colony-stimulating factor (GM-CSF).
TTP controls its expression by binding to the 3UTR of its own
mRNA, which also contains AREs (6, 34). Following stimula-
tion of macrophages by LPS, TTP is increasingly expressed in
multiple, differentially phosphorylated isoforms. While in-
creased expression of TTP is dependent on the activation of
the p38 pathway (9, 27), TTP is a direct substrate for MK2 in
vitro and in vivo, and the mouse protein is phosphorylated at
two major sites: serine 52 (S52) and S178 (12). Furthermore,
TTP can be directly phosphorylated by p38 (10, 35). TTP is
recruited to stress granules (SGs) that are dynamic cytoplasmic
foci at which stalled translation initiation complexes accumu-
late in cells subjected to environmental stress (19). Phosphor-
ylation of TTP by MK2 at S52 and S178 excludes TTP from
arsenite-induced SGs and promotes the assembly of TTP–14-
3-3 complexes, leading to the inhibition of TTP-dependent
degradation of ARE-containing transcripts (32).
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The mechanism by which TTP regulates specific ARE-de-
pendent mRNA degradation is not completely understood so
far. In a cell-free system, TTP stimulates deadenylation of
ARE-containing transcripts (22). Recently, in TTP and its ho-
molog BRF-1, two domains which are necessary for its activity,
an N-terminal domain and a C-terminal domain, have been
identified (26). While the N-terminal domain was shown to
recruit mRNA decay enzymes, the C-terminal domain obvi-
ously binds other trans-acting factors. Interestingly, TTP could
also be involved in a microRNA16-mediated mechanism of
ARE-dependent mRNA degradation and directly interact with
components of the RISC complex but not with the microRNA
itself (17).
Here we provide genetic evidence that TTP is the major
target of MK2 involved in the posttranscriptional regulation of
TNF. The removal of TTP from an MK2-deficient background
completely reverses the low-TNF phenotype of MK2 knock-
out, TNF mRNA becomes stable, and high TNF levels are
produced, leading to a phenotype similar to that of TTP defi-
ciency alone. We demonstrate that MK2 is required for main-
tenance of normal TTP levels, and phosphorylation by MK2
leads to stabilization of TTP and also to inhibition of its
mRNA destabilization activity.
MATERIALS AND METHODS
Cell lines, vectors, and materials. WT and MK2/ macrophage cell lines
were produced as previously described (3). The expression of F4/80, Mac3,
Gr-1,B7.1, B7.2, and FcR was tested by fluorescence-activated cell sorting. The
MK2 deficiency in MK2/ cells was confirmed by reverse transcription-PCR.
TNF and IL-6 production were about 10% of WT in MK2/, similar to what
was previously described for primary cells (20). The AU-rich element of the
3UTR of TNF was cloned by the annealing of primers 5CTA GAT ATT TAT
ATT TGC ACT TAT TAT TTA TTA TTT ATT TAT TAT TTA TTT ATT
TGC TTA TGA ATG TAT TTA TTT G3 and 5GAT CCA AAT AAA TAC
ATT CAT AAG CAA ATA AAT AAA TAA TAA ATA AAT AAT AAA TAA
TAA GTG CAA ATA TAA ATA T3 and cloning into pBluescript KS BamHI
and XbaI sites. Vectors pcDNA3.1-mycHisA, pcDNA3-TTP-mycHisA, pcDNA3-
TTP-S52A-mycHisA, pcDNA3-TTP-S178A-mycHisA, and pcDNA3-TTP-AA-
mycHisA were provided by G. Stoecklin (32). SAK21A anti-TTP antibody was
previously described (27). 9E10 anti-myc antibody was obtained from superna-
tant of hybridoma cell culture. Recombinant murine macrophage colony-stimu-
lating factor (M-CSF) was from R&D systems (Minneapolis, Minn.). SB203580
and SB202190 were from Calbiochem (La Jolla, Calif.).
Generation of mutant mice. All mice used in this study were maintained under
specific-pathogen-free conditions. MK2 and TTP knockout mice were generated
as described previously (20, 33). TTP/ mice were bred to MK2/ mice to
obtain MK2/ TTP/ mice; F2 littermates were genotyped by PCR and used
for the experiments described below.
Mouse pathology. During mouse autopsy, all tissues were collected and fixed
in 10% neutral-buffered formalin. Samples of skin, heart, lung, spleen, liver,
kidney, pancreas, peripheral lymph nodes, foreleg with joints, hind leg with
joints, eyes, and conjunctival membranes were routinely embedded in paraffin
and stained with hematoxylin and eosin. Each organ was examined for patho-
logical changes by light microscopy using an Olympus BX41 microscope.
Bone marrow-derived macrophage (BMDM) preparation. Bone marrow-de-
rived macrophages were obtained from marrow plugs flushed from mice femurs
with 2.5 ml of ice-cold complete medium. Typically, material from one mouse
was cultured in two 10-cm plates in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 10 ng
of M-CSF/ml, 100 g of streptomycin/ml, and 100 U of penicillin/ml at 37°C.
After 2 and 6 days, the cells were washed and grown in fresh medium for a total
of 9 to 10 days. The cells appeared to be 100% macrophages according to
morphology.
Affinity purification. Affinity purification was performed as previously de-
scribed (4) with the following modifications. Linearized vector was used as
template for in vitro transcription using the T7-MEGAshortscript kit (Ambion,
Huntingdon, United Kingdom) according to instructions of the manufacturer,
except that CTP was mixed 2:1 with biotin-14-CTP (Gibco/Life Technologies,
Inchinnan, Scotland). Cells were grown to 70 to 80% confluence on 10-cm plates,
washed with cold phosphate-buffered saline (PBS), and lysed by resuspension in
200 l low-salt lysis buffer (20 mM HEPES, pH 7.5, 50 mM KCl, 2 mM MgCl2,
0.5 mM dithiothreitol [DTT], 10% protease inhibitor cocktail complete mini
EDTA-free [Roche, Mannheim, Germany], phosphatase inhibitor cocktails I and
II at 10% each [Sigma], and 0.2% Nonidet P-40), and incubated on ice for 10
min. The lysates were then centrifuged at 800  g. Affinity purification was
carried out in batch at 4°C. Streptavidin agarose beads (30 l/assay; Gibco/Life
Technologies, Inchinnan, Scotland) were equilibrated by three washes with bind-
ing buffer (20 mM HEPES, pH 7.5, 150 mM KCl). The RNA pellet from
transcription was resuspended in binding buffer, and 10 to 20% of the transcrip-
tion reaction in 20 l was added to 30-l beads. KCl (1 M) was added to extracts
to reach a salt concentration of 160 mM. After addition of RNase inhibitor (0.4
U/l), heparin, and tRNA (final concentrations of 5 mg/ml and 0.2 mg/ml,
respectively), 60 l of material was incubated with RNA-loaded beads for 90 min
at 4°C. After extensive washing with buffer (20 mM HEPES, pH 7.5, 150 mM
KCl, 2 mM MgCl2, 0.5 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 5%
glycerol, and 0.1% Nonidet P-40), 2 sodium dodecyl sulfate (SDS) loading
buffer was directly added to beads and incubated for 5 min at 95°C. After a short
centrifugation, the supernatant containing the loading buffer and proteins was
directly loaded on SDS-polyacrylamide gel electrophoresis (PAGE) gels.
Alkaline phosphatase treatment. Macrophage lysates were prepared in low-salt
lysis buffer as described for affinity purification. Calf intestinal alkaline phosphatase
(CIP) (NEB Biolabs) was used for dephosphorylation. Twenty-six microliters of
lysate in 1 NEB buffer 3 was incubated with 10 U CIP at 37°C for 15 min. Control
lysates were incubated under the same conditions but without CIP.
Western blot. For Western blot analysis, the protein concentration was mea-
sured and 4 Laemmli’s sodium dodecyl sulfate (SDS) sample buffer was added
(40% glycerol, 4% SDS, 4% -mercaptoethanol, 0.4 M Tris-HCl, pH 6.7, and 2
mg/ml bromphenol blue). Samples were boiled, briefly centrifuged, and resolved
by SDS-polyacrylamide gel electrophoresis (10% acrylamide), and proteins were
transferred from the gels to Hybond ECL membranes (Amersham Pharmacia
Biotech). Blots were incubated for 2 h in PBS–1% Tween 20 (PBST) containing
5% powdered skim milk. After three washes with PBST, membranes were incu-
bated for 1 h with the primary antibody and for 1 h with horseradish peroxidase-
conjugated secondary (2,000-fold diluted). Bound antibodies were detected with
an ECL detection kit (Santa Cruz Biotechnology).
TTP protein stability experiments in macrophages. Cells were induced with 1
g/ml LPS for 2 h. Subsequently, SB203580 (10 M final concentration), cyclo-
heximide (7 M final concentration), or SB203580 and cycloheximide together
were added. Because SB203580 stock was dissolved in dimethyl sulfoxide
(DMSO), in control samples lacking SB203580 equal volumes of DMSO were
added. After different times, lysates were obtained by direct resuspension in 2
SDS loading buffer. Quantification of protein was done according to reference
18, and equal or, where indicated, different amounts of protein were applied to
Western blots using the SAK21A anti-TTP antibody.
Green fluorescent protein (GFP)-TTP stability. Cells were seeded at a 1:2
ratio and grown overnight in DMEM plus 10% FCS. The next day the cells were
harvested by gentle scraping. A total of 2  106 cells/point were nucleofected
with 5 g DNA containing 500 ng pEGFPc1-TTP using a nucleofector with
solution T and program T-20 (Amaxa, Cologne, Germany). Replicate transfec-
tions were combined before seeding into 6-well plates to control for differences
in transfection efficiency. The cells were cultured in RPMI plus 20% FCS for 2 h
and then either left untreated or stimulated with LPS (10 ng/ml) for 1.75 h.
Cycloheximide (5 g/ml) was added to the LPS-stimulated cells for 15 min, and
then the unstimulated and 1 LPS-stimulated points were harvested and cyto-
plasmic extracts were prepared (27). The remaining cells were treated with either
0.1% DMSO or 1 M SB202190 for 2 h and then harvested as described above.
One-hundred micrograms of cytoplasmic extract was applied to Western blots
using the SAK21A anti-TTP antibody.
Detection of mRNA and determination of RNA stability. Macrophages were
treated with 1 g/ml LPS (Escherichia coli; Sigma L-6529) for the time points
indicated before addition of actinomycin D (2 g/ml) for the indicated time.
Total cellular RNA was obtained from macrophage cultures using a QIAGEN
mini RNA kit, typically from 80% confluent 6-cm tissue culture plates. RNA
concentration was determined by spectrophotometrical measurement at 260 nm.
Appropriate amounts of RNA were separated on 1.2% agarose-formaldehyde
gels and blotted onto nitrocellulose membrane. The filters were probed with
33P-labeled mouse cDNA using RAPID-HYBbuffer (Amersham Biosciences).
TNF measurement. BMDM were scratched from 10-cm plates and counted,
and 3  104 cells were transferred to a 48-well plate and incubated in 0.5 ml
medium for 2 h before addition of 1 g/ml LPS for 4 h. TNF was measured in
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macrophage supernatant by enzyme-linked immunosorbent assay (Quantikine M
mouse TNF immunoassay kit; R&D Systems).
Transfection of HEK293 cells. HEK293 cells were cultured in DMEM con-
taining 10% FCS. These cells were maintained in 5% CO2 at 37°C. Cells at about
60% confluence were transfected by the Lipofectamine method (Life Technol-
ogies, Inc.). After incubation for 12 h, the transfected cells were washed with
DMEM and incubated in fresh growth medium for 24 h.
RESULTS
TTP is the main downstream element of MK2 in the post-
transcriptional regulation of TNF. TTP/ mice were crossed
with MK2/ mice and backcrossed with the F1 generation,
leading to MK2/ TTP/ double knockout animals. Bone
marrow-derived macrophages were isolated from these ani-
mals and stimulated with 1 g/ml LPS, and the TNF content of
culture supernatants was analyzed by enzyme-linked immu-
nosorbent assay (ELISA) 4 h after stimulation. Remarkably,
MK2 TTP double knockout macrophages show strongly in-
creased amounts of TNF almost identical to that of TTP-
deficient mice (Fig. 1A). We also analyzed TNF production in
vivo after LPS challenge of mice with the different genotypes.
It can be seen that TNF levels in both TTP-deficient and TTP-
and MK2-deficient mice is comparably increased compared to
the wild type, while the TNF level is reduced in MK2-deficient
animals (Fig. 1B). Hence, TTP deficiency completely abolishes
the deleterious effect of MK2 deficiency on TNF production,
indicating that TTP is genetically downstream of MK2.
TNF mRNA levels and stability were analyzed by stimulat-
ing macrophages for 2 h with LPS and arresting transcription
by actinomycin D. The level of TNF mRNA is comparable in
TTP/ and MK2/ TTP/ macrophages and is higher than
that in WT or MK2/ cells (Fig. 1C). In MK2-deficient cells,
the stability of TNF mRNA is lower that in the WT control,
while in the TTP-deficient background the lack of MK2 does
not alter TNF mRNA stability significantly (Fig. 1D). This
indicates that the action of MK2 is necessary for stabilization
of TNF mRNA upon LPS treatment and that the differences in
TNF mRNA stability depend on the presence of TTP.
Pathology of MK2 TTP double knockout mice. We were
interested to learn whether the similarity in the increase in
TNF production in TTP- and TTP- and MK2-deficient mice
results in a comparable phenotype. First, like TTP knockout
mice, TTP MK2 double knockout mice had reduced growth,
associated with cachexia and the “Kangaroo” hunched posture
which is characteristic for many inflammatory syndromes in
mice. Like TTP knockout mice, TTP MK2 double knockout
mice showed reddened and swollen paw joints. Light micro-
scopic examinations revealed that both TTP knockout and
TTP MK2 double knockout mice had a moderate to severe
inflammatory infiltration with neutrophils and plasma cells
in numerous tissues, including the periarticular soft tissue
and the conjunctival membranes, while WT and MK2-defi-
cient mice did not show such infiltrations (Fig. 2). Our
observations indicated that TTP MK2 double knockout mice
show a phenotype comparable to that of TTP knockout mice
described previously (33).
TTP expression is down-regulated in MK2-deficient cells.
After having established the genetic relationship between TTP
and MK2, we were interested in the molecular mechanism
responsible for this relationship. Inhibition of p38 by SB208530
FIG. 1. MK2 TTP double knockout macrophages produce TNF
protein and mRNA levels comparable to those of TTP-deficient cells.
(A) TNF ELISA of macrophage culture supernatants. BMDM from
three mice were pooled, grown for 10 days, harvested, and counted,
and equal numbers of cells were transferred to a 48-well plate. Cells
were induced with LPS or left untreated as control (C) for 4 h. TNF
levels in the supernatants were measured by ELISA. Where indicated,
10 M SB203580 (SB) was added 1 h prior to LPS stimulation. For
each genotype, three independent measurements were made, and
averages and standard deviations are shown. The experiment is rep-
resentative for four similar experiments. (B) Three mice of each ge-
notype were injected intraperitoneally with LPS (5 mg per kg of body
weight) diluted in PBS. The TNF level in serum was measured before
and 90 min after injection. Before injection, serum TNF levels were
below the detection limit of ELISA. Levels after 90 min for each
mouse (asterisk) and mean values for each genotype () are indicated.
(C) Bone marrow from three WT, three MK2/, three TTP/, and
three MK2/ TTP/ mice were pooled, and macrophages were
grown in 10-cm plates for 10 days. After induction for 2 h with 1 g/ml
LPS, 2 g/ml actinomycin D (Act D) was added for 30 and 60 min.
Total RNA was prepared, and 10 g RNA was used for Northern blot
analysis with a TNF probe. The same blot was reused for the -actin
control. This experiment is representative of two independently per-
formed experiments. (D) Quantification of the Northern blot shown in
panel C. The intensity of the TNF mRNA bands was quantified using
TINA software (Raytest, Staubenhardt, Germany) and normalized to
actin mRNA. The calculated half-lives for TNF mRNA are the fol-
lowing: WT, 130 min; MK2/ TTP/, 307 min; TTP/, 350 min;
and MK2/, 51 min.
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leads to a significant reduction of the LPS-induced TTP pro-
tein expression in RAW264.7 macrophages (27, 34). Since it
was not clear whether this effect is MK2 dependent, we ana-
lyzed TTP levels in bone marrow-derived primary macro-
phages, in immortalized macrophage cell lines, and in spleen
from MK2-deficient mice after LPS stimulation by Western
blotting. It can be seen that protein levels of TTP are reduced
in all MK2-deficient samples (Fig. 3A to C). In contrast, in WT
cells, TTP was induced by LPS stimulation and expressed in
multiple differentially phosphorylated forms that show differ-
ent mobilities in SDS-PAGE. Treatment with alkaline phos-
phatase leads to the collapse of the phosphorylated bands to
one, probably nonphosphorylated band (Fig. 3D). In MK2-
deficient cells, alkaline phosphatase treatment leads only to
FIG. 2. MK2 TTP double knockout mice share the pathology of TTP knockout mice. Both the TTP knockout mice and the TTP MK2 double
knockout mice had moderate to severe infiltrations with neutrophils and plasma cells (arrows) in numerous tissues, including the periarticular soft
tissue (left panels) and the conjunctival membranes (right panels). WT and MK2 knockout mice showed no infiltrations. Bar, 100 m.
2402 HITTI ET AL. MOL. CELL. BIOL.
a weak shift of the already weaker phosphorylated TTP
population.
Northern blot analysis revealed a significant reduction of
TTP mRNA after LPS induction in immortalized MK2/
macrophages compared to WT macrophages, whereas TNF
and -actin mRNA levels were comparable between MK2/
and WT mice under the same conditions (Fig. 4). RNA stabil-
ity experiments indicate that TTP mRNA is less stable in
MK2/ cells, suggesting an MK2-dependent stabilizing effect
on TTP mRNA (Fig. 4C). Taken together, we suggest that
MK2 is an important downstream kinase of p38 responsible for
the regulation of TTP at the posttranscriptional level.
The p38/MK2 pathway can stabilize TTP by phosphoryla-
tion. The p38/MK2 signaling pathway regulates the levels of
mRNA, protein, and phosphorylation of TTP (10, 12, 27, 35).
We decided to analyze whether this pathway also regulates the
stability of TTP. Bone marrow-derived primary macrophages
were grown to 80% confluence and induced with LPS for 2 h,
leading to expression and phosphorylation of TTP (Fig. 5A,
lane 2 h LPS). Subsequently, cycloheximide and/or SB203580
was added to inhibit protein translation and/or p38 MAPK.
Interestingly, addition of SB203580 reduced the TTP protein
level compared to that of the control. This indicates that the
p38 pathway has a stabilizing function on TTP protein. In
addition, the TTP band that accumulates in the cycloheximide
control migrates slower compared to the TTP band in the
presence of SB203580, indicating higher stability of the phos-
phorylated forms of TTP. To assay the role of MK2 for this
stabilization, the TTP level was analyzed at different times
after blocking protein translation in immortalized MK2-defi-
cient macrophages and in control WT macrophages (Fig. 5B).
It can be seen that TTP is less stable in MK2/ macrophages
than in WT macrophages. The estimated half-life of TTP in
WT cells is about 9 h, while in MK2/ cells it is about 2.5 h.
To exclude transcriptional effects of the p38 inhibition and
to understand the role of the identified phosphorylation sites
for MK2, S52, and S178, we also analyzed regulation and
stability of a cytomegalovirus promoter-driven GFP-TTP fu-
sion protein and the appropriate mutant GFP-TTP-S52,178A
in RAW 264.7 cells and in MK2-deficient macrophages (Fig.
5C). First, the GFP-TTP-S52,178A mutant is weakly detect-
able and significantly less stable than WT GFP-TTP, whether
expressed in RAW 264.7 or MK2/ macrophages, indicating
that these phosphorylation sites are essential for stabilization.
FIG. 3. TTP protein expression is reduced in MK2-deficient cells.
(A) TTP levels in total lysates from WT and MK2-deficient bone
marrow-derived primary macrophages that were induced with 1 g/ml
LPS for the times indicated were analyzed by Western blot. (B) Total
lysates from WT and MK2-deficient immortalized macrophage cell
lines induced with LPS and analyzed by Western blot. (C) TTP West-
ern blot analysis of spleen lysates from mice that were injected with 100
g LPS for 2 h. (D) Alkaline phosphatase causes a collapse of TTP
from lysate of LPS induced immortalized WT macrophages to a single
band, indicating that the slower motility is due to phosphorylation.
FIG. 4. TTP mRNA is unstable in MK2-deficient macrophages.
(A) WT and MK2/ immortalized macrophages were induced with 1
g/ml LPS for the times indicated and used for total RNA preparation
and Northern blotting (10 g total RNA per lane). (B) WT and
MK2/ immortalized macrophages were induced with 1 g/ml LPS
for 45 min before addition of 2 g/ml actinomycin D (ActD) for the
times indicated. Ten micrograms of total RNA was loaded per lane for
WT and 30 g total RNA per lane for MK2/. After development
with the TTP probe, Northern blots were stripped and rehybridized
with a TNF probe and/or -actin probe as control. (C) Quantification
of the Northern blot shown in panel B. The intensity of the TTP
mRNA bands was quantified and normalized to actin mRNA. A half-
life for TTP mRNA of 34 min in MK2-deficient macrophages and 63
min in WT cells could be calculated.
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Second, LPS induction leads to an up-regulation of GFP-TTP
in RAW cells but not in MK2-deficient cells, suggesting that
phosphorylation by MK2 in RAW cells stabilizes TTP. Third,
SB203580 treatment in the presence of cycloheximide leads to
a down-regulation of GFP-TTP in RAW 264.7- but not MK2-
deficient cells (Fig. 5C, compare GFP-TTP lanes for LPS at
4 h, CHX at 2 h, and SB and SB), indicating that part of the
p38-dependent TTP stabilization is due to MK2. Taken to-
gether, these findings support the notion that phosphorylation
by MK2 at S52 and/or S178 contributes to an LPS-induced
stabilization of TTP.
Phosphorylation of TTP decreases its ability to bind the
TNF mRNA 3UTR. MK2 is able to phosphorylate TTP both in
vivo and in vitro, and major sites of phosphorylation were
identified as serine residues S52 and S178 (12, 27). After LPS
induction, TTP is detected in multiple differentially phosphor-
ylated forms that migrate with different mobilities in SDS-
PAGE (see, for example, Fig. 3). To test whether some of the
phosphorylated forms of TTP display higher levels of binding
to TNF-ARE, we performed affinity purification experiments
using in vitro-transcribed biotinylated ARE of TNF mRNA
coupled to streptavidin beads and protein lysates from LPS-
induced WT macrophages. In the supernatant (Fig. 6A, S),
differently phosphorylated isoforms of TTP can be detected,
especially after LPS treatment (lane S). Affinity purification
(Fig. 6A, lane A) demonstrates preferential binding of a
band with faster mobility and, thus, lower phosphorylation to
the 3UTR of TNF, while TTP does not bind to streptavidin
agarose itself (lane C). To analyze whether phosphorylation of
TTP by MK2 at the serine residues identified is responsible for
the apparent inhibition of binding, we performed affinity pu-
rification experiments using HEK293 cells transfected with
myc-tagged phosphorylation site mutants TTP-S52A, TTP-
S178A, and TTP-S52,178A. Before lysis, the transfected cells
were incubated for 1 h with 100 M arsenite to stimulate p38.
Protein lysates were used for affinity purification on TNF-ARE
as described above. Comparison of the intensity of affinity
purified TTP bands (A) with the bands from the supernatant
(S) gives an indication for the strength of binding (Fig. 6B).
Interestingly, TTP mutants containing the S178A substitution
(TTP-S178A and TT-AA) have a slightly stronger binding to
TNF-ARE than WT or TTP-S52A (Fig. 6B, lane TTP S52A,
A), suggesting a reduction in ARE binding of TTP by phos-
FIG. 5. Phosphorylation by MK2 stabilizes TTP. (A) Bone marrow-
derived primary macrophages were induced for 2 h with 1 g/ml LPS.
At this time point, either SB203580 (SB), cycloheximide (CHX), or SB
and cycloheximide were added for 2 h. The addition of SB destabilizes
TTP protein; in the absence of SB and the presence of cycloheximide,
a higher phosphorylation band accumulates. (B) Immortalized WT
and MK2/ macrophages were induced for 2 h with LPS. Subse-
quently, cycloheximide was added to stop translation. Cells were lysed
after an additional 1, 2, 3, and 4 h of incubation. Fifty micrograms of
total lysate from WT cells and 150 g of total lysate from MK2/ cells
was loaded. (C) Stability of transfected GFP-TTP and GFP-TTP-S52/
178A mutant. RAW cells and MK2/ immortalized macrophages
were transfected with GFP-TTP and GFP-TTP-S52/178A. Four hours
after transfection, LPS was added for 2 h and, subsequently, SB202190
(SB) and cycloheximide (CHX) were added as indicated for a further
2 h.
FIG. 6. Phosphorylation reduces the affinity of TTP to TNF-ARE.
Shown are affinity purification experiments using biotin-labeled in
vitro-transcribed TNF-ARE coupled to streptavidin beads. (A) Protein
lysates from immortalized WT macrophages that were induced with 1
g/ml LPS were used for affinity purification (A, affinity purified; S,
supernatant). The least phosphorylated TTP band with high mobility
shows the strongest binding. C, negative control using beads that are
not coupled to RNA and lysates of LPS-induced macrophages. (B)
myc-tagged WT TTP and mutants with serine-to-alanine substitutions
at serine 52 (TTP-S52A) and/or at serine 178 (TTP-S178A) and
TTP-AA were overexpressed in HEK293 cells. One hour prior to lysis,
100 M arsenite was added to activate the p38 pathway. Lysates were
used for affinity purification as described for panel A. C, negative
control using beads that are not coupled to RNA and lysates from TTP
transfected cells. myc stands for the empty vector control. This exper-
iment is representative of two independently performed experiments.
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phorylation, especially at S178. This effect is rather subtle, and
apparent differences in binding of the differently phosphory-
lated isoforms between those shown in Fig. 6A and B exist,
which might arise from the fact that in Fig. 6A endogenous
protein from LPS-treated macrophages is analyzed, while in
Fig. 6B myc-tagged forms of TTP overexpressed in HEK293
cells stimulated with arsenite are used.
Inhibition of p38 reduces TTP levels in MK2/ macro-
phages and TNF levels in TTP/ MK2/ macrophages. We
were interested to determine whether MK2 is the only down-
stream element necessary and sufficient for the p38-dependent
regulation of TTP expression. TTP expression levels were an-
alyzed in MK2/ macrophages after SB203580 treatment and
LPS induction. p38 inhibition reduced TTP levels in WT mac-
rophages and, to a somewhat lesser extent, also in MK2/
macrophages to basal levels, indicating the presence of another
p38 downstream element in the regulation of TTP expression
or a direct p38 effect on TTP levels (Fig. 7).
It has been described that TTP-deficient cells have a de-
creased sensitivity to p38 inhibitors (10). We were interested to
know if the MK2/TTP pathway is sufficient and necessary to
exert the effect of p38 on TNF production. We analyzed TNF
production of MK2 TTP double knockout macrophages in the
presence or absence of the p38 inhibitor. Interestingly, TNF
expression in TTP/ and TTP MK2 double knockout macro-
phages is significantly inhibited by SB203580 (Fig. 1A). These
results support the above notion that p38 is directly involved or
has a downstream element other than the MK2-TTP module
that also contributes to the regulation of TNF protein expres-
sion.
DISCUSSION
Genetic evidence that TTP is downstream of MK2 in post-
transcriptional regulation. Upon LPS stimulation, MK2-defi-
cient macrophages produce levels of TNF mRNA similar to
those of WT macrophages but express only about 10% of the
WT level of TNF protein. In contrast, TTP-deficient cells pro-
duce elevated levels of TNF mRNA and protein. Here, we
demonstrated that the removal of TTP from an MK2-deficient
genotype completely reversed the MK2-deficient phenotype
and that the resulting MK2- and TTP-double-deficient macro-
phages produce levels of TNF mRNA and protein similar to
those of the TTP knockout. This, together with previous re-
ports that TTP can be phosphorylated by MK2 (12, 27), pro-
vides strong evidence that TTP is downstream of MK2 in the
regulation of both stability and translation of TNF mRNA.
MK2 stabilizes and inactivates TTP by phosphorylation.
The results obtained suggest the following mechanism for the
posttranscriptional regulation of TNF biosynthesis by the p38
MAPK signaling pathway (Fig. 8). Upon LPS, p38 is stimu-
lated, and it phosphorylates and activates MK2. Activity of
MK2 is essential for stabilization of TTP mRNA and protein as
well as for stabilization of TNF mRNA. In addition to being
essential for TTP expression, MK2 could also inhibit TTP’s
destructive activity against TNF mRNA by the same phosphor-
ylations that stabilize the protein. This effect could be based on
reduced binding of TTP to the ARE of TNF mRNA and/or on
its increased binding to 14-3-3 proteins (10, 32). As a result,
TNF mRNA is efficiently expressed and translated. In a second
phase of the response to LPS (designated “recovery” in Fig. 8),
where p38 and MK2 activity is back to basal levels, TTP could
then be dephosphorylated and activated, and it can down-
regulate TNF mRNA by destabilization in parallel to its own
degradation. One may speculate that binding of TTP to ARE
FIG. 7. Inhibition of p38 down-regulates the level of TTP protein
in MK2-deficient macrophages. Western blot for TTP and GAPDH as
a control of total protein lysates from macrophages that were induced
with 1 g/ml LPS for 2 or 4 h. SB203580 (SB) was added 1 h prior to
addition of LPS to a final concentration of 10 M. Addition of
SB203580 leads to a reduction of TTP protein levels in WT cells
compared to the LPS-stimulated control and, to a lesser extent, also in
MK2/ cells compared to the LPS-stimulated MK2-deficient control.
FIG. 8. Model of posttranscriptional regulation by the p38/MK2/TTP
pathway in response to LPS in the different genetic situations. TTP is
expressed in small amounts in nonstimulated cells (no stress), is not
phosphorylated, and is able to bind and destabilize rare TNF mRNA
occasionally transcribed and, hence, elevates the threshold of inflamma-
tion. In the case of stimulation by LPS, the rate of TNF and TTP tran-
scription increases, and MK2 gets activated, phosphorylates TTP, and
reduces its binding to ARE, making ARE-containing mRNA stable.
Phosphorylated TTP protein is stable, and its accumulation can be im-
portant in the recovery step, when MK2 is no longer active and TTP is
rapidly dephosphorylated. Dephosphorylated TTP binds to and destabi-
lizes TNF mRNA, resulting in decreasing expression of TNF. Apparently,
in MK2-deficient cells, codegradation of nonphosphorylated TTP bound
to TNF mRNA becomes the default pathway, resulting in low levels of
both components, and causes alleviation of inflammatory response. In
contrast, TTP-deficient mice which are compromised in degradation of
ARE-containing mRNAs produce increased levels of TNF upon LPS
stimulation and, even in the absence of stimulation, develop TNF excess
syndrome. Since TTP is downstream of MK2, TNF excess syndrome is not
modulated by MK2 deficiency in the absence of TTP.
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or components of the degradation machineries is a prerequi-
site for its destabilization and that mRNA destabilizing activity
and degradation of TTP itself is coupled at the exosome or
RISC/micro RNP complex (17). Alternatively, a codegradation
of TTP and ARE mRNAs in a proteasome-dependent manner
seems possible (23, 24). Apparently, in MK2-deficient cells,
codegradation of TTP together with TNF mRNA becomes the
default pathway, resulting in low levels of both components.
However, in WT cells the above scenario requires the presence
of a phosphatase(s) that possibly activates TTP. The stabiliza-
tion of TTP by the p38 pathway and its accumulation in an
inactive form, which can be activated by dephosphorylation
when the p38 pathway is turned off, is of plausible physiological
relevance for limiting the inflammatory response. Interestingly,
preliminary results indicate a significant positive effect of phos-
phatase inhibitors on TTP expression and stability (E. Hitti
and M. Gaestel, unpublished data).
The nonphosphorylated form of TTP is the active form. The
idea that the nonphosphorylated form of TTP is active in
posttranscriptional repression of TNF expression is supported
by two independent observations. First, the high levels of TNF
production in the TTP MK2 double knockout compared to
reduced TNF production in MK2 knockout mice indicates that
the remaining TTP in MK2 knockout mice, which is not phos-
phorylated by MK2, actively contributes to repression of TNF
production. In contrast, the high level of phosphorylated TTP
in the WT has a reduced ability to inhibit TNF expression.
Second, affinity purification suggests that TTP mutants that
cannot be phosphorylated at serine 178 have a slightly in-
creased ability to bind ARE compared to WT TTP. This find-
ing is in accordance with the previously described stronger
ability of TTP to bind ARE after alkaline phosphatase treat-
ment (10). Phosphorylation of TTP at serine 52 and serine 178
also increases its binding to 14-3-3 protein and prevents its
entry into stress granules, where TNF mRNA is stored (27).
Hence, the reduced binding of phospho-TTP in the affinity
purification can also be due to competitive binding to 14-3-3
proteins in the lysate.
MK2 and TTP are not the only factors in regulation of
LPS-induced TNF production. Inhibition of p38 in MK2-defi-
cient cells further reduces the level of TTP. This observation
demonstrates that although MK2 plays a significant role in
regulation of TTP expression and stabilization, other down-
stream targets of p38 that influence TTP expression and/or
stability could exist. Since p38 has been demonstrated to phos-
phorylate TTP directly at several sites (8, 10, 35), direct mod-
ification of TTP by p38 is probably one additional mechanism
involved. It is also possible that p38 plays a role in the regu-
lation of TTP transcription. Interestingly, it is known that MK2
stabilizes p38 MAPK and that the p38 level is reduced in
MK2-deficient cells (21). Hence, direct contributions of p38
can be at least partially inhibited in the MK2-deficient cells.
Interestingly, TNF production can partially be inhibited by
SB203580 also in TTP- and MK2-deficient cells. Since it is
unlikely that SB203580 inhibits transcriptional activation of the
TNF gene (5), a role of further downstream targets of p38 on
posttranscriptional regulation of TNF expression seems possi-
ble, while the involvement of direct targets of MK2, such as
hnRNP-A0 (29) or PABP-1 (4), can be excluded. Interestingly,
a role of MAPK-interacting kinases, another group of kinases
downstream of p38, in posttranscriptional regulation of TNF
via hnRNP A1 has been recently described (7).
Regulation of other ARE-containing transcripts. TTP regu-
lates it own expression by binding to AU-rich elements of its
own mRNA (6, 34). It is therefore probable that the posttran-
scriptional regulation of TTP itself is similar to the regulation
of TNF. We observed that the half-life of TTP mRNA is short
in LPS-stimulated WT macrophages (about 60 min) and fur-
ther decreased in MK2-deficient cells (about 30 min). An ex-
planation could be that directly after translation, nonphosphor-
ylated TTP binds to the 3UTR of its own mRNA due to
spatial vicinity, a situation that does not occur with other AU-
rich transcripts. This could also explain the potency of the
ARE of TTP which belongs to group IV AREs containing only
two AUUUA pentamers. We have observed increased levels
and stability of other transcripts that contain AREs in both
TTP/ and MK2 TTP double knockout cells after stress in-
duction (data not shown). Hence, it is unlikely that TTP has
different functions on different transcripts. TTP itself does not
have nuclease domains and probably acts as a scaffolding pro-
tein (26). The differences in stability between ARE-containing
transcripts, as in the case of IL-6 and TNF, are probably due to
other ARE-binding factors, such as HuR, AUF1, AUF2,
FBP1, FBP2 (KSRP), TIA-1, and TIAR (14, 28). Together
with some of these proteins, TTP not only destabilizes ARE-
containing transcripts but could also inhibit translation. Be-
cause of the relatively high level of transcription of TNF
mRNA in LPS-stimulated cells, translational control of TNF
mRNA is the best known example so far.
Interestingly, there are examples where no effects of the p38
pathway were detected on ARE-containing transcripts (16, 20).
It is also possible that the p38 pathway acts differently on the
posttranscriptional level in different cell types depending on
the expression of ARE binding proteins (9, 16, 25). Differences
in the same cell type on different ARE-containing transcripts
could be due to differences in kinetics of mRNA transcription
and activation of the p38 pathway. In the case of TNF, upon
LPS treatment both TNF mRNA transcription and p38 activity
in WT and MK2/ macrophages peaks at approximately the
same time between 30 to 60 min after induction (data not
shown), which results in major p38 effects. However, when the
induction of transcription is slow and the activation of the p38
pathway is not maintained, its effect on other ARE-containing
transcripts would be only marginal.
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